Unknown

Dataset Information

0

Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease.


ABSTRACT: Parkinson's disease is typically treated with oral dopamine replacement therapies. However, long-term use is complicated by motor fluctuations from intermittent stimulation of dopamine receptors and off-target effects. ProSavin, a lentiviral vector based gene therapy that delivers local and continuous dopamine, was previously shown to be well tolerated in a Phase I/II first-in-human study, with significant improvements in motor behavior from baseline at 1 year. Here, patients with Parkinson's disease from the open-label trial were followed up in the long term to assess the safety and efficacy of ProSavin after bilateral injection into the putamen. Fifteen patients who were previously treated with ProSavin have been followed for up to 5 years, with some having been seen for 8 years. Eight patients received deep brain stimulation at different time points, and their subsequent assessments continued to assess safety. Ninety-six drug-related adverse events were reported (87 mild, 6 moderate, 3 severe) of which more than half occurred in the first year. The most common drug-related events were dyskinesias (33 events, 11 patients) and on-off phenomena (22 events, 11 patients). A significant improvement in the defined "off" Unified Parkinson's Disease Rating Scale part III motor scores, compared to baseline, was seen at 2 years (mean score 29?·?2 vs. 38?·?4, n?=?14, p?

SUBMITTER: Palfi S 

PROVIDER: S-EPMC6157351 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease.

Palfi Stéphane S   Gurruchaga Jean Marc JM   Lepetit Hélène H   Howard Katy K   Ralph G Scott GS   Mason Sarah S   Gouello Gaëtane G   Domenech Philippe P   Buttery Philip C PC   Hantraye Philippe P   Tuckwell Nicola J NJ   Barker Roger A RA   Mitrophanous Kyriacos A KA  

Human gene therapy. Clinical development 20180901 3


Parkinson's disease is typically treated with oral dopamine replacement therapies. However, long-term use is complicated by motor fluctuations from intermittent stimulation of dopamine receptors and off-target effects. ProSavin, a lentiviral vector based gene therapy that delivers local and continuous dopamine, was previously shown to be well tolerated in a Phase I/II first-in-human study, with significant improvements in motor behavior from baseline at 1 year. Here, patients with Parkinson's di  ...[more]

Similar Datasets

| S-EPMC8158710 | biostudies-literature
| S-EPMC3666632 | biostudies-literature
| S-EPMC5374069 | biostudies-literature
| S-EPMC3794457 | biostudies-literature
| S-EPMC9153043 | biostudies-literature
| S-EPMC5509559 | biostudies-literature
| S-EPMC6637939 | biostudies-literature
| S-EPMC6681249 | biostudies-literature
| S-EPMC7655016 | biostudies-literature
| S-EPMC8117394 | biostudies-literature